当前位置:考试网  > 试卷库  > 技能鉴定  > 科技类  > 通信计算机技能考试  > 计算机打字复印工  >  纸盒不能供纸故障原因与排除方法
试题预览

纸盒不能供纸故障原因与排除方法

查看答案
收藏
纠错
正确答案:

复印机的搓纸轮大多数靠电磁线圈的动作来控制。检查时需使机器处于有纸状态,可用透明胶纸将检测有无纸盒的开关粘住,使无纸信号不出现,将一小块纸放在检测纸盒的光电传感器上,按下开始复印键后,大约1~2秒钟后,控制搓纸轮的电磁线圈的衔铁应有吸台动作,如果无此动作,则应检查电磁线圈与线路板间的连线接触是否良好。如果有此动作,则应考虑搓纸离合器内的弹簧是否损坏;生锈,必要时应更换离合器。

答案解析:

暂无解析

你可能感兴趣的试题

为什么打印机产生滑座错误、甚至打印头撞头的现象?

为什么打印纸张进入打印机后走纸时,纸张会走歪

打印件上出现局部或全部字不清楚怎么办

打印机如何清洗打印头?

在打印件上,大字有锯齿状,文字出现一直线缺笔断划怎么办?

热门试题 更多>
试题分类: 计算机二级
练习次数:0次
1.The failure of a high-profile cholesterol drug has thrown a spotlight on the complicated machinery that regulates cholesterol levels.But many researchers remain confident that drugs to boost levels of 'good' cholesterol are still one of the most promising means to combat spiralling heart disease. 2.Drug company Pfizer announced on 2 December that it was cancelling all clinical trials of torcetrapib,a drug designed to raise heart-protective high-density lipoproteins (HDLs).In a trial of 15000 patients,a safety board found that more people died or suffered cardiovascular problems after taking the drug plus a cholesterol-lowering statin than those in a control group who took the statin alone. 3.The news came as a kick in the teeth to many cardiologists because earlier tests in animals and people suggested it would lower rates of cardiovascular disease."There have been no red flags to my knowledge," says John Chapman,a specialist in lipoproteins and atherosclerosis at the National Institute for Health and Medical Research (INSERM) in Paris who has also studied torcetrapib."This cancellation came as a complete shock." 4.Torcetrapib is one of the most advanced of a new breed of drugs designed to raise levels of HDLs,which ferry cholesterol out of artery-clogging plaques to the liver for removal from the body.Specifically,torcetrapib blocks a protein called cholesterol ester transfer protein (CETP),which normally transfers the cholesterol from high-density lipoproteins to low density,plaque-promoting ones.Statins,in contrast,mainly work by lowering the 'bad' low-density lipoproteins. Under pressure 5.Researchers are now trying to work out why and how the drug backfired,something that will not become clear until the clinical details are released by Pfizer.One hint lies in evidence from earlier trials that it slightly raises blood pressure in some patients.It was thought that this mild problem would be offset by the heart benefits of the drug.But it is possible that it actually proved fatal in some patients who already suffered high blood pressure.If blood pressure is the explanation,it would actually be good news for drug developers because it suggests that the problems are specific to this compound.Other prototype drugs that are being developed to block CETP work in a slightly different way and might not suffer the same downfall. 6.But it is also possible that the whole idea of blocking CETP is flawed,says Moti Kashyap,who directs atherosclerosis research at the VA Medical Center in Long Beach,California.When HDLs excrete cholesterol in the liver,they actually rely on LDLs for part of this process.So inhibiting CETP,which prevents the transfer of cholesterol from HDL to LDL,might actually cause an abnormal and irreversible accumulation of cholesterol in the body."You're blocking a physiologic mechanism to eliminate cholesterol and effectively constipating the pathway," says Kashyap.Going up 7.Most researchers remain confident that elevating high density lipoproteins levels by one means or another is one of the best routes for helping heart disease patients.But HDLs are complex and not entirely understood.One approved drug,called niacin,is known to both raise HDL and reduce cardiovascular risk but also causes an unpleasant sensation of heat and tingling.Researchers are exploring whether they can bypass this side effect and whether niacin can lower disease risk more than statins alone.Scientists are also working on several other means to bump up high-density lipoproteins by,for example,introducing synthetic HDLs."The only thing we know is dead in the water is torcetrapib,not the whole idea of raising HDL," says Michael Miller,director of preventive cardiology at the University of Maryland Medical Center,Baltimore. Questions 7-13 Match torcetrapib,HDLs,statin and CETP with their functions (Questions 8-13)..Write the correct letter A,B,C or D in boxes 8-13 on your answer sheet.NB You may use any letter more than once. 7.It has been administered to over 10,000 subjects in a clinical trial. 8.It could help rid human body of cholesterol. 9.Researchers are yet to find more about it. 10.It was used to reduce the level of cholesterol. 11.According to Kashyap,it might lead to unwanted result if it's blocked. 12.It produced contradictory results in different trials. 13.It could inhibit LDLs.List of choices A.TorcetrapicB.HDLSC.StatinD.CETP
试题分类: 阅读
练习次数:3次
试题分类: 初级(口语)
练习次数:1次
试题分类: 初级(口语)
练习次数:0次
扫一扫,手机做题